
In first open-label phase 3 data from the ADEPT program, KarXT cut hallucination and delusion scores in Alzheimer disease psychosis, with no new safety signals.
Click on the links below to download "2010 Staff Salary Survey: Regional Data" and "What Should You Pay Staff?"




